Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …

The introduction of selective tyrosine-kinase inhibitors (TKIs) for the treatment of chronic
myeloid leukaemia has changed patient outcome and, consequently, management of this …

The prognostic relevance of additional cytogenetic findings at diagnosis of chronic myeloid
leukemia (CML) is unclear. The impact of additional cytogenetic findings at diagnosis on …

Blast crisis (BC) remains the major challenge in the management of chronic myeloid
leukemia (CML). It is now generally accepted that BC is the consequence of continued BCR …

Targeted therapy in the form of selective tyrosine kinase inhibitors (TKI) has transformed the
approach to management of chronic myeloid leukemia (CML) and dramatically improved …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …

Abstract Purpose: On June 28, 2006, the US Food and Drug Administration approved
dasatinib (Sprycel; Bristol-Myers Squibb), a new small-molecule inhibitor of multiple tyrosine …